CJ signs license agreement with aRigen for exclusive marketing and sales of ARH-1029

Published: 2010-05-17 06:59:00

Updated: 2010-05-17 06:59:00

CJ Jeil Chedang said on May 12 that it signed a strategic alliance agreement with aRigen Pharmaceutical Inc., a drug discovery and development company focused on infectious diseases in Japan, for the exclusive marketing and sales of ARH-1029, a novel drug candidate for the treatment of peptic ulc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK